A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
NCT ID: NCT06702449
Last Updated: 2025-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
448 participants
INTERVENTIONAL
2024-11-19
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vaccine Against Escherichia Coli Infection
NCT02289794
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04020341
A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
NCT06597344
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04187144
Host Response to Urinary Tract Infection in Women
NCT00642070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1 Group A1/A2
Participants receive candidate UTI vaccine low dose formulation 1 or placebo on Day 1 and Day 61.
Candidate UTI vaccine low dose formulation 1
Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 1 Group B1/B2
Participants receive candidate UTI vaccine low dose formulation 2, or placebo on Day 1 and Day 61.
Candidate UTI vaccine low dose formulation 2
Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 1 Group C1/C2
Participants receive candidate UTI vaccine medium dose formulation 1, or placebo on Day 1 and Day 61.
Candidate UTI vaccine medium dose formulation 1
Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 1 Group D1/D2
Participants receive candidate UTI vaccine medium dose formulation 2, or placebo on Day 1 and Day 61.
Candidate UTI vaccine medium dose formulation 2
Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 1 Group E1/E2
Participants receive candidate UTI vaccine high dose formulation 1, or placebo on Day 1 and Day 61.
Candidate UTI vaccine high dose formulation 1
Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 1 Group F1/F2
Participants receive candidate UTI vaccine high dose formulation 2, or placebo on Day 1 and Day 61.
Candidate UTI vaccine high dose formulation 2
Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Part 2 Group 1
Participants receive the candidate UTI vaccine highest tolerated dose (HTD) formulation 2, tested in Part 1 of the study, on Day 1 and Day 61.
Candidate UTI vaccine HTD formulation 2
Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Part 2 Group 2
Participants receive placebo on Day 1 and Day 61.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candidate UTI vaccine low dose formulation 1
Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine low dose formulation 2
Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine medium dose formulation 1
Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine medium dose formulation 2
Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine high dose formulation 1
Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine high dose formulation 2
Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Candidate UTI vaccine HTD formulation 2
Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Placebo
Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent obtained from the participant prior to performance of any study-specific procedure.
* Female participants of non-childbearing potential may be enrolled in the clinical study.
* Female participants of childbearing potential may be enrolled in the clinical study, if the participant:
* has practiced adequate contraception for 1 month prior to study intervention administration, and
* has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire treatment period and for at least 1 month after completion of the study intervention administration series.
* Blood sample for simultaneous follicle stimulating hormone (FSH) and estradiol levels may be collected.
Additional inclusion criterion only for participants in Part 1 of the study (SLI):
* Female and male between and including 18 through 64 YOA at the time of ICF signature.
* Healthy participants, according to medical history, laboratory assessment and clinical examination at Screening Visit.
Additional inclusion criterion only for participants in Part 2 of the study (PoP):
* Females between and including 18 through 64 YOA at the time of ICF signature.
* Female participants with documented history of at least 1 episode of urine culture confirmed E. coli uncomplicated UTI in the last 12 months prior to study vaccine administration.
Exclusion Criteria
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* Hypersensitivity to latex.
* History of pIMD.
* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* History of endocrinologic, hematologic, metabolic, urologic, dermatologic, or gastrointestinal conditions that, in the opinion of the investigator, places the participant at unacceptable risk or would make adhering to study procedures for the duration of the study difficult.
* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory (including, but not limited to demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, or seizures.
* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
* Condition that in the judgment of the investigator would make intramuscular injection unsafe.
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
Additional exclusionary medical conditions only for participants in Part 1 of the study (SLI):
• Any clinically significant hematologic and/or biochemical laboratory abnormality at Screening Visit.
Additional exclusionary medical conditions only for participants in Part 2 of the study (PoP):
* The participant has UTI that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or any Enterobacter species.
* The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments.
* The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract.
* The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract.
* The participant who, in the opinion of the investigator, has an otherwise complicated UTI or has an active upper UTI.
* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period.
* Previous administration of a vaccine or immunostimulant targeting rUTI.
* Participants currently on a prophylactic agent for rUTI (including antibiotics, methenamine, D-mannose).
* Planned administration and/or administration of a vaccine not foreseen by the study protocol in the period starting 15 days before the first dose and ending 15 days after the last dose of study intervention(s) administration.
* Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.
* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study.
* Up to 3 months prior to the study intervention administration:
* For corticosteroids, this will mean prednisone equivalent \>=20 mg/day for adult participants. Inhaled and topical steroids are allowed.
* Up to 3 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.
* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine or invasive medical device).
* Pregnant or lactating female participant.
* Female participant planning to become pregnant or planning to discontinue contraceptive precautions before 1 month after completion of the study intervention administration series.
* History of chronic alcohol consumption and/or drug abuse, based on investigator judgment.
* Persons under guardianship or trusteeship.
* Persons deprived of liberty.
* Any study personnel or their immediate dependents, family, or household members.
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Secaucus, New Jersey, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Weatherford, Texas, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Wenatchee, Washington, United States
GSK Investigational Site
Johannesburg, , South Africa
GSK Investigational Site
Soshanguve, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
219685
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.